melanoma Archives
STINGing combination for cancer
Jun. 19, 2017—A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.
Melanoma study finds new way to enhance targeted therapies
Mar. 9, 2017—With the help of a drug formerly used to treat HIV/AIDS, researchers at Vanderbilt University Medical Center (VUMC) have found a way to make melanoma cells more vulnerable to targeted anti-cancer therapy.
Melanoma response to immune therapy
Mar. 3, 2016—Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.
Combining treatments for melanoma
Feb. 18, 2016—Combining therapies for melanoma that induce cell senescence and that activate the immune response may improve outcomes for patients.
Investigators find clues to melanoma treatment resistance
Oct. 29, 2015—Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.
Gene mutations may predict melanoma response to immunotherapies
Mar. 12, 2015—Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.
Study tracks combination therapy to treat melanoma
Jan. 8, 2015—Melanoma is the most lethal form of skin cancer, with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and the cancer advances.
Immune cell activity and melanoma
Nov. 6, 2014—The activity of a certain factor in immune cells is essential for an anti-tumor response, emphasizing the need to consider the effects of anti-cancer therapies on immune cells.
Indiana couple hits the links to support melanoma research
Oct. 16, 2014—A Vanderbilt-Ingram Cancer Center (VICC) melanoma patient is using his passion for golf to support melanoma research efforts at VICC.
VICC researchers in spotlight at national cancer conference
Jun. 19, 2014—New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations.
VU study identifies new gene fusions in melanoma
Dec. 19, 2013—Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer.
Foundation lauds graduate student’s melanoma research
Mar. 28, 2013—Katherine Hutchinson, a third-year graduate student in Cancer Biology at Vanderbilt University, has won a $10,000 Research Scholar Award from the Joanna M. Nicolay Melanoma Foundation.
